JP2020503852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503852A5 JP2020503852A5 JP2019529555A JP2019529555A JP2020503852A5 JP 2020503852 A5 JP2020503852 A5 JP 2020503852A5 JP 2019529555 A JP2019529555 A JP 2019529555A JP 2019529555 A JP2019529555 A JP 2019529555A JP 2020503852 A5 JP2020503852 A5 JP 2020503852A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- gene
- acid molecule
- isolated nucleic
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 210000001153 interneuron Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 108010035848 Channelrhodopsins Proteins 0.000 claims description 3
- 108010050754 Halorhodopsins Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003068 molecular probe Substances 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022003202A JP2022062041A (ja) | 2016-12-01 | 2022-01-12 | インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16201747.9 | 2016-12-01 | ||
| EP16201747 | 2016-12-01 | ||
| PCT/EP2017/080827 WO2018099974A1 (en) | 2016-12-01 | 2017-11-29 | Synp107, a promoter for the specific expression of genes in interneurons |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003202A Division JP2022062041A (ja) | 2016-12-01 | 2022-01-12 | インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503852A JP2020503852A (ja) | 2020-02-06 |
| JP2020503852A5 true JP2020503852A5 (enExample) | 2021-01-14 |
| JP7071361B2 JP7071361B2 (ja) | 2022-05-18 |
Family
ID=57460428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529555A Active JP7071361B2 (ja) | 2016-12-01 | 2017-11-29 | インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７ |
| JP2022003202A Withdrawn JP2022062041A (ja) | 2016-12-01 | 2022-01-12 | インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003202A Withdrawn JP2022062041A (ja) | 2016-12-01 | 2022-01-12 | インターニューロン中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ１０７ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190376082A1 (enExample) |
| EP (1) | EP3548093A1 (enExample) |
| JP (2) | JP7071361B2 (enExample) |
| CN (1) | CN110072559A (enExample) |
| WO (1) | WO2018099974A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2679246A3 (en) | 2008-04-18 | 2014-02-26 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapeutical tools and methods for treating blindness |
| US10941417B2 (en) | 2015-04-30 | 2021-03-09 | Friedrich Miescher Institute For Biomedical Research | Promoter for the specific expression of genes in Müller cells |
| US10857241B2 (en) | 2015-09-15 | 2020-12-08 | Friedrich Miescher Institute For Biomedical Research | Therapeutical tools and methods for treating blindness by targeting photoreceptors |
| WO2017064642A1 (en) | 2015-10-14 | 2017-04-20 | Fredrich Miescher Institute For Biomedical Research | Promoter for the specific expression of genes in retinal endothelial cells |
| ES2886664T3 (es) | 2015-12-03 | 2021-12-20 | Friedrich Miescher Institute For Biomedical Res | SynP162, un promotor para la expresión específica de genes en fotorreceptores de bastón |
| US10994026B2 (en) | 2015-12-03 | 2021-05-04 | Friedrich Miescher Institute For Biomedical Research | SynP160, a promoter for the specific expression of genes in rod photoreceptors |
| WO2017093935A1 (en) | 2015-12-03 | 2017-06-08 | Friedrich Miescher Institute For Biomedical Research | Synp161, a promoter for the specific expression of genes in rod photoreceptors |
| ES2909444T3 (es) | 2015-12-03 | 2022-05-06 | Friedrich Miescher Institute For Biomedical Res | Synp159, un promotor para la expresión específica de genes en los fotorreceptores de los bastones |
| CA3042197A1 (en) | 2016-11-02 | 2018-05-11 | Friedrich Miescher Institute For Biomedical Research | Synp198, a promoter for the specific expression of genes in direction selective retinal ganglion cells |
| CN110392582A (zh) | 2017-02-08 | 2019-10-29 | 弗里德里克·米谢尔生物医学研究所 | 用于使基因在视网膜神经节细胞中特异性表达的启动子SynP88 |
| EP3634350B1 (en) | 2017-06-05 | 2021-10-06 | The Procter & Gamble Company | Configurable absorbent articles having improved bodily exudate visualization |
| WO2019097454A1 (en) | 2017-11-15 | 2019-05-23 | Friedrich Miescher Institute For Biomedical Research | Primate retinal pigment epithelium cell-specific promoter |
| WO2019106035A1 (en) | 2017-11-30 | 2019-06-06 | Friedrich Miescher Institute For Biomedical Research | Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium |
| EP3927302B1 (en) | 2019-02-21 | 2024-11-13 | The Procter & Gamble Company | Absorbent articles having fully removable fastening members |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3104895A1 (en) * | 2014-02-10 | 2016-12-21 | Friedrich Miescher Institute for Biomedical Research | Aii retinal amacrine cell-specific promoter |
-
2017
- 2017-11-29 CN CN201780072403.9A patent/CN110072559A/zh not_active Withdrawn
- 2017-11-29 WO PCT/EP2017/080827 patent/WO2018099974A1/en not_active Ceased
- 2017-11-29 US US16/464,475 patent/US20190376082A1/en not_active Abandoned
- 2017-11-29 JP JP2019529555A patent/JP7071361B2/ja active Active
- 2017-11-29 EP EP17816563.5A patent/EP3548093A1/en not_active Withdrawn
-
2022
- 2022-01-12 JP JP2022003202A patent/JP2022062041A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503852A5 (enExample) | ||
| JP2020501538A5 (enExample) | ||
| Espinoza et al. | SINEUP non-coding RNA targeting GDNF rescues motor deficits and neurodegeneration in a mouse model of Parkinson’s disease | |
| JP2019537437A5 (enExample) | ||
| Wang et al. | Mouse γ-synuclein promoter-mediated gene expression and editing in mammalian retinal ganglion cells | |
| Choi et al. | FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation | |
| US20200149068A1 (en) | Chimeric capsids | |
| JP2021502813A5 (enExample) | ||
| JP2021503934A5 (enExample) | ||
| JP2020533959A (ja) | Ａａｖを送達するための組成物および方法 | |
| JP2021503933A5 (enExample) | ||
| CN113543814B (zh) | 用于治疗肾病综合征的aav基因疗法 | |
| Crabtree et al. | AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis | |
| Tan et al. | Lentiviral vector-mediated expression of exoenzyme C3 transferase lowers intraocular pressure in monkeys | |
| AU2016354988A1 (en) | Secreted splicing variant of mammal Klotho as a medicament for cognition and behaviour impairments | |
| JP2019519515A (ja) | アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法 | |
| Vacca et al. | AAV-mediated gene therapy in Dystrophin-Dp71 deficient mouse leads to blood-retinal barrier restoration and oedema reabsorption | |
| Abdullah et al. | Targeted deletion of T‐cell S1P receptor 1 ameliorates cardiac fibrosis in streptozotocin‐induced diabetic mice | |
| JP2025016506A (ja) | 二本鎖ｒｎａ及びその使用 | |
| Lebœuf et al. | ENGRAILED‐1 transcription factor has a paracrine neurotrophic activity on adult spinal α‐motoneurons | |
| Palko et al. | ER‐stress response in retinal Müller glia occurs significantly earlier than amyloid pathology in the Alzheimer's mouse brain and retina | |
| US20160144055A1 (en) | Gene therapy vector for treatment of steroid glaucoma | |
| Li et al. | Safflower extract and aceglutamide injection promoting recovery of peripheral innervations via vascular endothelial growth factor-B signaling in diabetic mice | |
| CN112353940B (zh) | 一种用于预防或治疗抑郁症的药物及其应用 | |
| Zhang et al. | circSIRT2/miR‐542‐3p/VASH1 axis regulates endothelial‐to‐mesenchymal transition (EndMT) in subretinal fibrosis in age‐related macular degeneration models |